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Brucella ovis causes ram contagious epididymitis, a disease for which a specific vaccine is lacking. Attenuated Brucella
melitensis Rev 1, used as vaccine against ovine and caprine brucellosis caused by B. melitensis, is also considered the
best vaccine available for the prophylaxis of B. ovis infection, but its use for this purpose has serious drawbacks. In this
work, two previously characterized B. ovis attenuated mutants (Δomp25d and Δomp22) were evaluated in mice, in
comparison with B. melitensis Rev 1, as vaccines against B. ovis. Similarities, but also significant differences, were found
regarding the immune response induced by the three vaccines. Mice vaccinated with the B. ovis mutants developed
anti-B. ovis antibodies in serum of the IgG1, IgG2a and IgG2b subclasses and their levels were higher than those
observed in Rev 1-vaccinated mice. After an antigen stimulus with B. ovis cells, splenocytes obtained from all
vaccinated mice secreted similar levels of TNF-α and IL12(p40) and remarkably high amounts of IFN-γ, a crucial
cytokine in protective immunity against other Brucella species. By contrast, IL-1α -an enhancer of T cell responses
to antigen- was present at higher levels in mice vaccinated with the B. ovis mutants, while IL-10, an anti-inflammatory
cytokine, was significantly more abundant in Rev 1-vaccinated mice. Additionally, the B. ovis mutants showed appropriate
persistence, limited splenomegaly and protective efficacy against B. ovis similar to that observed with B. melitensis Rev 1.
These characteristics encourage their evaluation in the natural host as homologous vaccines for the specific prophylaxis
of B. ovis infection.Introduction
Brucellosis caused by Brucella ovis mainly induces chronic
epididymitis and orchitis in rams. The disease is widely
distributed and constitutes one of the most important
causes of reproductive failure in sheep [1]. In addition
to a reduction in male fertility, B. ovis induces occasional
abortions in ewes and increases the risk of perinatal mor-
tality and low weight in lambs, thus having an important
economic impact in the livestock sector [1].
Brucella strains are smooth (S) or rough (R), depending
on the presence or absence of O-polysaccharide (O-PS)
chains in the lipopolysaccharide (LPS) respectively. Other
outer membrane (OM) components -such as OM proteins
(OMPs) or the core and lipid A of LPS- are masked by
O-PS in S strains, while in R brucellae, such as B. ovis, they* Correspondence: vizcaino@usal.es
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unless otherwise stated.are exposed on the bacterial surface [2]. In infected animals
and humans, the O-PS chains induce a strong antibody
response that constitutes the basis for the serological
diagnosis of infections caused by S Brucella strains [2].
Brucella melitensis Rev 1 is an S live attenuated strain
currently used for vaccination campaigns against ovine
and caprine brucellosis, which is almost exclusively
caused by B. melitensis and B. ovis. It is also considered
the best vaccine available for the prophylaxis of B. ovis
infection despite being mainly used for preventing B.
melitensis infection [3-7]. However, several drawbacks are
associated with Rev 1 vaccine, such as its variable efficacy,
the induction of antibodies against S-LPS interfering with
the diagnosis of brucellosis caused by B. melitensis and
other S brucellae, the ability to induce human infections
and abortions in animals and its resistance to streptomycin
[5,8,9]. Additionally, due to its serological cross-reactivity
with other S Brucella strains, it is banned in countries
where B. melitensis has been eradicated, some of which areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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constitute a serious problem. Therefore, the development
of a new vaccine able to substitute B. melitensis Rev 1
strain in the prophylaxis of B. ovis infection is a matter of
great interest.
Subcellular vaccines based on the hot saline extract
(HS) of B. ovis -mainly composed of R-LPS and OMPs-
have been extensively analyzed in mice and rams but
their protective activity is limited [10-14]. Among these
vaccines, HS encapsulated in microparticles has provided
the best results in terms of protection [12]. R-LPS and/
or recombinant proteins, either as purified antigens or
as DNA vaccines requiring repeated inoculations, have
also been assayed, with different success rates [13-17].
Considering that the best vaccines available against
brucellosis caused by S Brucella strains are homologous
S live attenuated strains [18], the development of an R
B. ovis attenuated vaccine strain seems to be an inter-
esting approach for the control of B. ovis infection.
In light of the above, the aim of this work was to
evaluate the immunogenicity and protective activity against
B. ovis infection of two B. ovis attenuated mutants obtained
previously by inactivation of the genes coding for Omp25d
and Omp22 [19], two OMPs of the Omp25/Omp31 family
[20,21]. Considering that routine analysis of Brucella
vaccines in the natural host is precluded due to econom-
ical and practical difficulties [22], the murine model was
selected for this purpose since it is proposed by the World
Organisation for Animal Health (OIE) as a method for the
evaluation of Brucella vaccines administered in sheep [23]
and it is currently used in brucellosis research for the
assessment of the protective activity of vaccines [22,24].
Additionally, a good correlation between the mouse model
and sheep has been observed for other Brucella vaccines
[25] and the B. ovis attenuated mutants have been ana-
lyzed in parallel with B. melitensis Rev1 -the attenuated
strain used in official vaccination campaigns against sheep
brucellosis [3,23]- that constitutes a control of recognized
vaccine efficacy in the natural host.
Materials and methods
Bacterial strains and culture conditions
The Brucella strains used in this work are shown in Table 1.
The R virulent B. ovis PA strain and smooth (S) attenuated
B. melitensis Rev 1 classical vaccine were obtained from theTable 1 Brucella strains used in this work
Strain Origina Virulence (relevant genotype)
B. melitensis Rev 1 BCCN V4a Classical attenuated vaccine
B. ovis PA BCCN 76-250 Virulent strain
B. ovis PNV25dA [19] Recombinant B. ovis PA attenuated m
B. ovis PNV22A [19] Recombinant B. ovis PA attenuated m
aBCCN, Brucella Culture Collection, Nouzilly, France.Institut National de la Recherche Agronomique, Nouzilly,
France. Attenuated B. ovis PNV25dA (Δomp25d) and B.
ovis PNV22A (Δomp22) are mutant strains derived from
virulent B. ovis PA [19]. They were obtained previously
by substitution of omp25d or omp22, respectively, by a
kanamycin (Kan) resistance gene [19].
All Brucella strains were propagated in tryptic soy agar
(Pronadisa-Laboratorios Conda, Torrejón de Ardoz, Spain)
supplemented with 0.3% yeast extract (Pronadisa-Labora-
torios Conda) and 5% horse serum (Gibco-Life Technolo-
gies, Grand Island, USA) (TSA-YE-HS). When appropriate,
depending on the resistance profile of each Brucella strain
(Table 1), streptomycin (Strep) or Kan (Sigma-Aldrich, St.
Louis, USA) was added to TSA-YE-HS medium to a final
concentration of 50 μg/mL. Bacteria were incubated at
37 °C in a 5% CO2 atmosphere.
Mice and inoculation procedure
Female 6-week-old BALB/c mice (Charles River Labora-
tories, Chatillon-sur-Chalaronne, France), received at our
laboratory one week previously, were used. They were
randomly distributed into experimental groups and kept
with water and food ad libitum in the animal experimen-
tation facilities of the University of Salamanca (registration
number PAE SA-001). Procedures with mice were designed
according to Spanish and European legislation regarding
the use of animals in research (RD 1201/05 and directive
2010/63/UE).
Vaccination and challenge with Brucella strains were
performed by intraperitoneal inoculation of bacterial
suspensions in phosphate-buffered saline (PBS; pH 7.2)
prepared from fresh cultures incubated for 44 h. The
number of colony-forming units per mL (CFU/mL) was
estimated by optical density (OD) readings at 600 nm
(OD600) and the exact doses administered were deter-
mined retrospectively by triplicate plating of the properly
diluted inocula on TSA-YE-HS.
Immunization of mice and sample collection for evaluation
of the immune response and vaccine strain persistence
Mice were inoculated with PBS (unvaccinated control),
with the B. melitensis Rev 1 classical vaccine (105 CFU),
or with the Δomp25d (107 CFU) or Δomp22 (108 CFU)
mutants of B. ovis PA. The dose of vaccination for B.
melitensis Rev 1 was that commonly used for vaccineLPS phenotype Relevant antibiotic resistance
Smooth Streptomycin
Rough -
utant (Δomp25d) Rough Kanamycin
utant (Δomp22) Rough Kanamycin
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B. ovis attenuated mutants were selected according to
previous results of spleen colonization when they were
inoculated at a dose of 5 × 106 CFU/mice [19] and taking
into account vaccine studies with other Brucella species
[22]. Thus, considering that the Δomp22 mutant was
severely attenuated in that previous study [19], the dose of
108 CFU/mice was selected to analyze its vaccine proper-
ties, while vaccination with the Δomp25d mutant -that
showed a reduced persistence but a high level of spleen
colonization at week 1 post-inoculation (pi) (about 2 log
units higher than the parental strain) [19]- was performed
at a dose of 107 CFU/mice.
Sera for analysis of the antibody response were obtained
from submandibular blood extracted from five mice per
group at selected time-points. The same mice were
then euthanized and their spleens isolated in order to
determine both the CFU number of the vaccine strain
(persistence assay) and the cytokine profile.
To evaluate the ability of splenocytes from vaccinated
mice to secrete cytokines in response to a stimulus with
heat-inactivated B. ovis PA whole cells, five mice per
group were immunized as described above and their
spleens were removed 28 days later for further ex vivo
analysis of spleen cell cultures, as detailed below.
Evaluation of vaccine strain persistence
Persistence of the vaccine strains in mice was evaluated
by determining the bacterial CFU in spleen at 1, 3, 7, 14,
21, 28 and 49 days post-inoculation (dpi). At each se-
lected pi time-point, spleens from five mice per group
were weighed and individually homogenized in 9 vol
of Hanks’ balanced solution (Gibco-Life Technologies).
Ten-fold serial dilutions were plated onto TSA-YE-HS to
determine bacterial counts. The results were expressed as
means ± SD (n = 5) of the log CFU/spleen for each strain.
For each vaccination group, the mean ± SD (n = 5) of the
spleen weight in grams was also calculated.
Evaluation of the antibody response in serum against
whole cells of B. ovis
Serum immunoglobulin (Ig) G (IgG) titers in immunized
mice were determined by indirect enzyme-linked im-
munosorbent assay (i-ELISA) at 1, 3, 7, 14, 21, and 28
dpi (pre-challenge period in protection experiments).
Plates (96-well Maxisorp, Nunc-Thermo Fisher Scientific,
Roskilde, Denmark) were coated by overnight incubation
with 100 μL of B. ovis PA suspensions (OD600 = 1) prepared
in PBS from heat-inactivated (1 h, 65 °C) fresh cultures
(44 h of growth). The wells were then incubated
sequentially with 5% skim milk in PBS (30 min at 37 °C),
double-serial dilutions of mouse sera in PBS containing
0.05% Tween 20 (PBS-T; 1 h at 37 °C) and goat anti-
mouse IgG (Fc)-peroxidase conjugate (Sigma-Aldrich)diluted 1:4000 in PBS-T (1 h at room temperature). The
different steps were separated by three washes with 0.9%
NaCl, 0.05% Tween 20. Finally, the substrate solution –1
mM 2,2’-azino-di-(3-3-ethylbenzothiazoline-sulfonic acid)
(ABTS; Sigma-Aldrich) and 2 mM H2O2 (Sigma-Aldrich)
in 0.1 M citrate, pH 4.2- was added to the wells and the
OD405 readings were recorded on a Microplate Reader
550 (Bio-Rad, Hercules, USA) after 30 min incubation
at room temperature. IgG isotypes were determined
under the same conditions but using goat anti-mouse
IgG1-, IgG2a- or IgG2b-peroxidase conjugates (Santa Cruz
Biotechnology, Dallas, USA).
Antibody titers in serum were defined as the inverse of
the highest serum dilution scoring an OD405 value two
times higher than that obtained with the blank (mean
OD405 of six wells in which serum was replaced by dilu-
tion buffer). The results for IgG were represented as
means ± SD of the log of the titers obtained with five
mice analyzed individually. The results concerning IgG
isotypes were represented as means ± SD of the OD405
values obtained with a 1/100 dilution of a pool of the
five sera assayed in triplicate.
Evaluation of cytokines in spleen and in splenocyte cultures
Cytokine levels in the spleens of immunized mice were
evaluated at 1, 3, 7, 14, 21 and 28 dpi (pre-challenge
period in protection experiments). CHAPS (Sigma-Aldrich)
was added (1% final concentration) to mouse spleens
homogenized in Hanks balanced salt solution (Gibco-
Life Technologies) (see vaccine persistence section) [26,27].
After a 1-h incubation at 4 °C, cell debris was removed by
centrifugation and the supernatants were stored at −80 °C
until analysis. The levels of interferon-γ (IFN-γ), tumor
necrosis factor-α (TNF-α), interleukin-1α (IL-1α), IL-10
and IL-12(p40) were quantified by sandwich ELISA with
OptEIATM Mouse Sets specific to each cytokine, as
instructed by the manufacturer (BD Biosciences, San
Diego, USA) and described elsewhere [28]. The results for
each vaccination group were expressed as means ± SD of
the cytokine quantity (ng) detected in the spleens of five
individual mice at each time-point.
Cytokine production was also evaluated, after stimula-
tion with heat-inactivated B. ovis PA whole cells, in cell
cultures of splenocytes obtained from immunized mice
at 28 dpi. Uniform single-cell suspensions were prepared
by gentle disruption of spleens, as described previously
[28]. Cells were suspended in complete RPMI medium
(RPMI supplemented with 10% fetal calf serum, 4 mM
L-glutamine, 1 mM sodium pyruvate, 0.05 mM 2-mer-
captoethanol (Gibco-Life Technologies) and 100 μg/mL
gentamicin), distributed in 24-well plates (4 × 105 cells/
well in 1 mL) and cultured at 37 °C and a 5% CO2 atmos-
phere. Splenocytes were stimulated by exposure to heat-
inactivated (1 h at 65 °C) B. ovis PA whole cells (107 CFU/
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Aldrich) as a positive control of cell proliferation, or
culture medium as a negative control. The stimulating
agents were prepared in complete RPMI medium and
added to each well in 100-μL volumes. After 72 h, the
supernatants were harvested, centrifuged and stored
at –80 °C until use for cytokine quantification, performed
as described above. Two wells were used for each experi-
mental condition and mouse. The results for each vaccin-
ation group were expressed as means ± SD of the cytokine
amount (ng/well) in the supernatants of splenocytes
obtained from five individual mice. The results obtained
with the positive and negative controls (concanavalin A
and RPMI as stimulating agents, respectively) were as
expected and are not shown.
Protection studies in mice
Mice inoculated with PBS (unvaccinated control), B.
melitensis Rev 1 (105 CFU/mouse), B. ovis Δomp25d
(107 CFU/mouse) or B. ovis Δomp22 (108 CFU/mouse)
were challenged 28 days later with 105 CFU of virulent
B. ovis PA. Three weeks after the challenge (49 days
after immunization), the bacterial CFU numbers in spleen
were counted in five mice from each experimental group,
as described previously [19]. The CFU number of virulent
B. ovis PA in mice vaccinated with B. melitensis Rev 1
(Strep-resistant strain; Table 1) was obtained by subtract-
ing the CFU obtained in TSA-YE-HS-Strep medium from
those obtained in the same medium without antibiotic.
Similarly, differential counts in medium with and without
Kan were used to determine the CFU of the challenge
strain in the spleens of mice vaccinated with the B. ovis
attenuated strains. Results were expressed as means ± SD
(n = 5) of the log CFU/spleen of B. ovis PA for each
vaccination group.
Statistical analyses
Statistical comparisons between means were performed
using analysis of variance. The levels of significance of
the differences between the experimental groups were
determined with the post-hoc Fisher’s protected least
significant differences (PLSD) test.
Results
Persistence of vaccine strains in spleen
Spleen weight and bacterial counts were determined at
several pi time-points in mice inoculated with B. meliten-
sis Rev 1, B. ovis Δomp25d, and B. ovis Δomp22 (retro-
spectively determined doses of 0.9 × 105, 1.2 × 107, and
0.80 × 108 CFU/mouse, respectively).
Under the assay conditions, spleen colonization by B.
melitensis Rev1 and B. ovis Δomp25d was quite similar,
with a peak of about 7 log CFU/spleen at 1 week pi and
a progressive decrease in bacterial counts thereafter untilthe end of the experiment on day 49 pi (Figure 1A).
However, while the classic B. melitensis Rev 1 vaccine
was detected in most of the animals on days 28 and 49
pi, all mice inoculated with the B. ovis Δomp25d mutant
had cleared the infection by day 49 pi (according to the
detection limit of the technique) and only 1 out 5 five
mice showed bacteria in its spleen at day 28 pi. With the
B. ovis Δomp22 attenuated mutant, the highest level of
spleen colonization extended from day 3 to day 21 pi
and was 2 log units lower (about 5 log CFU/spleen) than
that obtained with the two other vaccines on day 7 pi.
Thereafter, B. ovis Δomp22 behaved similarly to the other
vaccines (Figure 1A).
Regarding spleen weight (Figure 1B), the two B. ovis
attenuated mutants did not induce significant inflamma-
tion of the spleen along the assay, while the B. melitensis
Rev 1 classic vaccine induced a strong transient spleno-
megaly, reaching its highest level at 14 dpi. At that
moment, spleen weight in the mice inoculated with B.
melitensis Rev 1 was about 4 times higher than that
observed in mice inoculated with the B. ovis mutants
(Figure 1B).
Antibody response against B. ovis induced by the
vaccines
The levels of serum IgG able to react with whole B. ovis
cells in i-ELISA were evaluated up to day 28 pi (pre-
challenge period in the protection experiments) in mice
inoculated, as described for the persistence assay, with
PBS (negative control group) or each of the three atten-
uated vaccines.
In mice immunized with the two B. ovis attenuated
mutants, the IgG response against whole B. ovis cells
became evident by day 7 pi and increased progressively
thereafter until the end of the experiment (Figure 2A).
On days 7 and 14 pi, IgG titers were higher in mice
immunized with B. ovis Δomp22 than in those immunized
with B. ovis Δomp25d, but they reached similar levels by
day 28 pi (Figure 2A). In comparison, the IgG response
in mice immunized with B. melitensis Rev 1 was delayed
and weaker, since detectable titers appeared on day 14 pi
and were lower than those observed with the B. ovis
vaccines at all time-points checked (Figure 2A). Inside each
vaccination group, no important differences were detected
in the proportion of the IgG1, IgG2a and IgG2b isotypes
(Figure 2B-D).
Spleen cytokines in vaccinated mice
The cytokine profile in spleen was also evaluated until day
28 pi in mice inoculated, as described for the persistence
assay, either with PBS or with the attenuated strains.
The highest levels of IFN-γ, TNF-α, IL-1α, IL-10 and
IL-12(p40) in spleen were detected in mice immunized
with B. melitensis Rev 1 (Figure 3). In this group of mice,
Figure 1 Kinetics of splenic infection and spleen weight in mice inoculated with the vaccines. B. melitensis Rev 1 (Bme Rev 1; 1 × 105 CFU/
mouse), B. ovis PNV25dA (Bov Δomp25d; 1 × 107 CFU/mouse), and B. ovis PNV22A (Bov Δomp22; 1 × 108 CFU/mouse) were used as vaccines. Results
are expressed as means ± SD (n = 5) of the log CFU/spleen (A) or spleen weight (B) at each time-point.
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on days 7 and 14 pi, with a production peak on day 14
pi, and a decrease thereafter until day 28 pi, when all
cytokines had levels similar to those detected in mice
inoculated with PBS (Figure 3). IL-10 production in the
Rev 1-vaccinated mice followed a similar pattern but
with a delay of 7 days, the highest levels being detected
on days 14 and 21 pi (Figure 3D). Whereas TNF-α and
IL-10 scored the lowest levels (about 1.5 and 2 ng/
spleen, respectively), the strongest response was obtained
with IL-1α and IL-12(p40) (maximum levels about 10 ng/
spleen) followed by IFN-γ (5 ng/spleen).
Although to a lesser extent than B. melitensis Rev 1,
B. ovis Δomp25d also induced the production in spleen
of all cytokines tested (Figure 3), with the exception of
IL-10 (Figure 3D). A peak of cytokine production was
observed on day 7 pi, which was followed by a progressive
decrease until day 28 pi, when no differences betweenFigure 2 Antibodies, reactive with whole B. ovis PA cells, in serum. M
and B. ovis PNV22A vaccine strains. IgG levels are expressed as means ± SD (n
IgG2a and IgG2b levels were represented as the OD405 values obtained in
from mice inoculated with B. ovis PNV25dA (B), B. ovis PNV22A (C) or B. m
in legend to Figure 1.the mice inoculated with B. ovis Δomp25d and the PBS-
inoculated mice were observed (Figure 3).
In general, the mice immunized with B. ovis Δomp22
did not show statistically significant differences in cyto-
kine production in spleen when compared with mice
inoculated with PBS (Figure 3). The exception was IL-12
(p40) on day 7 pi, whose concentration in spleen was
slightly higher in mice inoculated with B. ovis Δomp22
(Figure 3E).
Cytokine secretion by splenocytes of vaccinated animals
in response to a stimulus with B. ovis PA whole cells
Mice were immunized with B. melitensis Rev1, B. ovis
Δomp25d, B. ovis Δomp22 (retrospectively determined
doses of 0.9 × 105, 1.1 × 107, and 1.4 × 108 CFU/mouse,
respectively) or with PBS.
To evaluate the ability of spleen cells of the vaccinated
animals to respond to a second stimulus by antigen,ice were inoculated with PBS or the B. melitensis Rev 1, B. ovis PNV25dA,
= 5) of the log of IgG titers in i-ELISA at each time-point (A). IgG1,
i-ELISA with a 1/100 dilution of a pool of five sera (three repeats)
elitensis Rev 1 (D). See strain abbreviations and inoculation doses
Figure 3 Levels of cytokines in spleen. IFN-γ (A), TNF-α (B), IL-1α (C), IL-10 (D), and IL-12(p40) (E) were evaluated in the spleens of mice inoculated
with PBS or the B. melitensis Rev 1, B. ovis PNV25dA, and B. ovis PNV22A vaccine strains. See strain abbreviations and inoculation doses in legend to
Figure 1. Results are expressed as means ± SD (n = 5) of each cytokine amount in spleen at each time-point.
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heat-inactivated B. ovis PA and the cytokines secreted
were quantified after 72 h of incubation (see Materials
and Methods).
Splenocytes from mice immunized with B. melitensis
Rev 1 or with the two B. ovis attenuated mutants secreted
high levels of IFN-γ (ranging between 97 and 223 ng/well),
which was the most abundant cytokine, in response to the
second antigen stimulus with B. ovis PA (Figure 4A). By
contrast, IFN-γ production by splenocytes obtained fromFigure 4 Cytokine production by stimulated splenocytes obtained fro
inoculated with PBS or with B. melitensis Rev 1, B. ovis PNV25dA, and B. ovis PN
inoculation from five mice per group. Splenocytes were cultured as described
(107 CFU/well) for 72 h. Supernatants were analyzed by ELISA tests specific fo
expressed as means ± SD (n = 5) of each cytokine amount per well. See strain
differences (PLSD test) between mice inoculated with each vaccine and contr
P ≤ 0.005; *, P ≤ 0.05. Significant differences between mice inoculated with the
are represented in brackets following the same rule.mice inoculated with PBS was comparatively weak (about
5 ng/well; P < 0.0005) (Figure 4A).
The three attenuated vaccines induced the secretion
of TNF-α by stimulated spleen cells to a similar extent
and in amounts that were two times higher (P < 0.05)
than those detected in the group inoculated with PBS
(Figure 4B). Regarding the production of IL-1α, no differ-
ences were found between the stimulated splenocytes of
mice immunized with B. melitensis Rev 1 and those of the
control mice inoculated with PBS (Figure 4C). In contrast,m mice inoculated with PBS or the vaccine strains. Mice were
V22A vaccine strains. Spleen cells were obtained 28 days after vaccine
in Materials and methods and stimulated with heat-killed B. ovis PA
r IFN-γ (A), TNF-α (B), IL-1α (C), IL-10 (D), and IL-12(p40) (E). Results are
abbreviations and inoculation doses in legend to Figure 1. Significant
ol mice inoculated with PBS are marked as follows: ***, P ≤ 0.0005; **,
B. ovis attenuated strains and mice vaccinated with B. melitensis Rev 1
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ovis Δomp22 vaccination groups was about four times and
three times higher, respectively (Figure 4C).
A strong IL-10 response was detected in stimulated
spleen cells of mice immunized with the B. melitensis Rev
1 classic vaccine (Figure 4D), while the spleen cells of
mice vaccinated with the two B. ovis attenuated strains
behaved similarly to those obtained from mice immunized
with PBS (Figure 4D). Regarding the secretion of IL-12
(p40) by stimulated spleen cells, no statistically significant
differences were found between the mice immunized with
the attenuated Brucella strains and the control mice
immunized with PBS (Figure 4E).Protective efficacy of the attenuated mutants against
B. ovis infection
Mice immunized with PBS (negative immunization
control), B. melitensis Rev 1, B. ovis Δomp25d or B. ovis
Δomp22 (retrospectively determined doses of 0.9 × 105,
1.1 × 107, and 1.4 × 108 CFU/mouse, respectively) were
challenged 28 days after immunization with virulent B.
ovis PA (retrospectively determined dose of 0.9 × 105
CFU/mouse). Bacteria were counted in spleen 3 weeks
after the experimental infection.
The B. melitensis Rev 1 classic vaccine and the two
B. ovis attenuated strains conferred similar protection
(P > 0.05) against a challenge with B. ovis. When compared
to mice inoculated with PBS, the three attenuated vaccines
reduced spleen colonization of virulent B. ovis PA in the
order of 3 log units (Figure 5). Only the challenge strain
was isolated in mice vaccinated with B. ovis Δomp25d whileFigure 5 Protection conferred in mice against virulent B. ovis
PA by the Brucella vaccines. Mice were inoculated with PBS
(negative control), B. melitensis Rev 1, B. ovis PNV25dA, or B. ovis
PNV22A (see strain abbreviations and inoculation doses in legend to
Figure 1) and were challenged 28 days later with 105 CFU/mouse of
virulent B. ovis PA. Three weeks after infection, the CFUs of B. ovis PA
in spleen were counted in five mice per vaccination group. Results
are expressed as means ± SD (n = 5) of the log CFU/spleen of B. ovis
PA. Significant differences (PLSD test) between vaccination groups
are marked as described in the legend to Figure 4.the B. ovis Δomp22 and B. melitensis Rev 1 vaccine strains
were detected in 3 out 5 mice.
Discussion
B. melitensis Rev 1 is considered the best vaccine available
against B. ovis infection but it has important drawbacks
that constrain its use for the specific prophylaxis of
brucellosis caused by B. ovis [3-7]. Since live attenuated
vaccines have provided the best results in terms of
protection against infections caused by other Brucella
species [29-31], it is to be expected that an attenuated
strain would also be the best choice for a vaccine targeting
B. ovis infection. Smooth vaccine strains other than B.
melitensis Rev 1 (i.e. B. abortus S19 or B. suis S2) would
not avoid the interference with the serological diagnosis
of smooth strain infections and, consequently, are not
suitable vaccines. Theoretically, rough B. abortus RB51
would offer a good alternative because interference with
diagnosis would be minimized. However, in spite of the
rough surface phenotype of B. abortus RB51, the risk of
inducing O-PS antibodies cannot be ignored owing to the
presence of small amounts of O-PS in its cytoplasm [32]
and, more importantly, this attenuated vaccine proved to
be inefficient in preventing against B. ovis infection in
rams [6]. Moreover, although some cases of heterologous
protection have been reported, in livestock homologous
Brucella spp. are usually more protective than heterol-
ogous Brucella spp. [31]. Accordingly, a B. ovis attenuated
strain would likely be the most interesting candidate to
develop a specific vaccine against ram contagious epi-
didymitis. This hypothesis also seems to be supported
by the fact that B. ovis displays significant differences in
surface topology, outer membrane properties and anti-
genic behavior when compared to other Brucella species
[2,21,33-35].
Although a recent work has reported the ability of a B.
ovis attenuated mutant to induce an immune response
in a natural host [36] and another work has analyzed the
protective activity of a B. ovis mutant in a murine model
[37], the potential of attenuated B. ovis strains as vaccines
remains almost unexplored. Two B. ovis mutants defective
in Omp25d and Omp22 surface protein, have previously
been shown to display attenuated virulence in a mouse
model [19,38] and in the present work they were evaluated
as homologous live attenuated vaccines, in comparison to
heterologous B. melitensis Rev 1, for the prophylaxis of
B. ovis infection.
In a previous study, when inoculated at a dose of 5 ×
106 CFU/mouse the Δomp22 mutant of B. ovis PA was
almost undetectable in spleen from week 1 pi [19], while
the Δomp25d mutant displayed a more moderate attenu-
ation, with even higher spleen colonization during the
initial stages of infection than that of the parental strain
but with a rapid clearance thereafter [19]. However,
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CFU/mouse, even though maximum bacterial counts
were 2 log units lower than those of B. melitensis Rev 1,
the persistence in spleen of B. ovis Δomp22 was similar
to that observed for the Rev 1 vaccine (Figure 1A) at the
dose commonly used for protection studies in mouse
models [22] and also in this work. The increase in the
inoculation dose of the Δomp25d mutant led to a spleen
growth curve that exhibited the same pattern as that
observed for the classic vaccine B. melitensis Rev 1 under
our assay conditions of (Figure 1A). Accordingly, the re-
quirement of a certain degree of persistence considered
necessary for an efficacious vaccine against Brucella spp.
[39,40] seems to have been accomplished with the B. ovis
Δomp25d and Δomp22 mutants, since their evolution in
spleen was similar to that observed with a recognized
control of vaccine efficacy against B. ovis (Figure 1A).
B. melitensis Rev 1 induced a strong inflammatory re-
sponse in spleen, this response reaching its highest level
of intensity on day 14 pi, while B. ovis Δomp25d, with a
spleen colonization profile similar to that of B. melitensis
Rev 1 (Figure 1A), and B. ovis Δomp22 only elicited a
moderate degree of splenomegaly (Figure 1B). Spleen
inflammation in the mice inoculated with B. melitensis
Rev 1 correlated with the high levels of cytokines de-
tected in this organ, since with the exception of IL-10 all
the cytokines peaked on day 14 pi (Figure 3), concomi-
tantly with spleen weight (Figure 1B). In these mice,
the maximum spleen levels of IL-10 were reached one
week later (Figure 3D), which, considering the anti-
inflammatory role proposed for this cytokine, could
reflect a mechanism aimed at counterbalancing the dele-
terious effects in the host derived from the exacerbated
inflammatory response [41,42]. This hypothesis seems
to be supported by the fact that the increase in IL-10
observed in mice vaccinated with B. melitensis Rev 1
(Figure 3D) was accompanied by a striking reduction in
both spleen weight (Figure 1B) and the amount of the
other cytokines analyzed (Figure 3). The reduction in
cytokine levels continued until day 28 post-vaccination,
when they reached the basal values observed in mice
inoculated with PBS or with the B. ovis-derived vaccines
(Figure 3). Since the challenge with virulent B. ovis PA
was performed at that moment, the protection afforded
by the vaccines cannot be attributed to residual cyto-
kines from the primary immunization. However, vaccin-
ation with B. melitensis Rev 1 or the attenuated Δomp22
and Δomp25d strains of B. ovis induced a memory immune
response that could be activated by B. ovis cells and that was
evidenced by the pattern of cytokine secretion when sple-
nocytes obtained from vaccinated mice were re-stimulated
ex vivo with killed B. ovis PA whole cells (Figure 4).
The strong inflammatory response -revealed by the
prominent increase in spleen weight and cytokine levels-detected in the spleens of mice vaccinated with B.
melitensis Rev 1 with respect to that induced by the B.
ovis vaccines (Figures 1B and 2) would initially predict
a better protective activity for the former vaccine.
However, the protection conferred by B. ovis Δomp25d
and Δomp22 against an experimental B. ovis infection
was equivalent to that of B. melitensis Rev 1 (Figure 5),
and several reasons can be invoked to explain this.
First, the higher response of antibodies able to bind to
B. ovis whole cells detected in mice immunized with
the B. ovis-derived vaccines (Figure 2) constitutes an
advantageous characteristic of the homologous vaccines
over B. melitensis Rev 1, since a more prominent role for
antibodies than for T lymphocytes has been identified
in protective immunity against B. ovis [43]. Second, the
level of IFN-γ, which is known to play a critical role in
the control of primary and secondary Brucella infections
[44,45], secreted by spleen cells from immunized mice in
response to exposure to B. ovis whole cells was remark-
ably high (ranging between 97 and 223 ng/well) in the
three vaccination groups (Figure 4A). Third, splenocytes
from mice vaccinated with the B. ovis-derived vaccines
secreted more IL-1α, which has been shown to be a potent
enhancer of CD4 and CD8 T cell responses to antigen
[46], than splenocytes obtained from mice vaccinated with
B. melitensis Rev 1 or non-vaccinated mice (Figure 4C).
Finally, re-stimulated spleen cells of mice vaccinated with
the B. ovis attenuated mutants did not differ from those
obtained from non-vaccinated mice regarding the produc-
tion of IL-10, while vaccination with B. melitensis Rev 1
induced an intense IL-10 response in re-stimulated
splenocytes. Considering the anti-inflammatory role pro-
posed for this cytokine [41,42], this might also constitute
an advantage for the B. ovis attenuated vaccines.
Some of these valuable characteristics of B. ovis Δomp25d
and Δomp22 are probably related to a more specific im-
mune response induced when homologous vaccines are
used. Despite the antigenic differences described for B.
ovis in comparison with other Brucella species, only a
moderate degree of antigenic diversity is expected between
B. melitensis Rev 1 and B. ovis PA, considering the high de-
gree of DNA identity shared by them [47]. However, S-LPS
is the major immunodominant antigen in smooth strains
such as B. melitensis Rev 1 [48,49], while R-LPS and OMPs
are immunodominant components in rough B. ovis that
lack S-LPS [50]. Accordingly, an important percentage of
the immune response developed after vaccination with B.
melitensis Rev 1 would probably not be effective against
later infection by B. ovis. By contrast, the immune response
triggered by the B. ovis attenuated vaccines would target
homologous antigens during a B. ovis infection and would
theoretically be more efficient in controlling the disease.
Another positive aspect of B. ovis Δomp25d and Δomp22 is
that their protective activity is accompanied by a limited
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would prevent undesirable effects associated with inflam-
mation in the host, as described for the classic vaccines
B. abortus S19 and B. melitensis Rev 1 [51,52].
According to the results reported here, the attenuated
strains B. ovis Δomp25d and Δomp22 induce a solid im-
mune response, with mixed Th1 and Th2 components,
able to control later infection by B. ovis as efficiently as
vaccination with heterologous B. melitensis Rev 1. Con-
sidering the drawbacks of vaccination with B. melitensis
Rev 1 [5,8,9], especially for the prophylaxis of B. ovis in-
fection, the attenuated vaccines analyzed here constitute
a promising alternative as specific vaccines against ram
contagious epididymitis that merits further evaluation
in the natural host and the analysis of alternative for-
mulations that might increase protective activity, such
as microencapsulation for sustained release, as described
for other Brucella vaccines [51,52].
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